Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use

Infectious Diseases and Therapy

Volumn 2, Issue 2, 2013, Pages 209-215

  Bosso, John A ^a,b   Haines, Martha L ^a   Gomez, Juanmanuel ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Amikacin; Aminoglycosides; Antibiotic resistance; Antibiotic usage; Escherichia coli; Gentamicin; Infectious diseases; Klebsiella pneumoniae; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG DATABASE; DRUG USE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 84977100581     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-013-0016-4     Document Type: Article

References (20)

1. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002-2006. Arch Intern Med. 2008;168: 2254-60.
2. Ababneh M, Harpe S, Oinonen M, Polk RE. Trends in aminoglycoside use and gentamicin-resistant Gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012;33: 594-601.
3. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 1991;35: 1284-90.
4. Weinstein RA, Nathan C, Gruensfelder R, Kabins SA. Endemic aminoglycoside resistance in Gram-negative bacilli: epidemiology and mechanisms. J Infect Dis. 1980;141: 338-45.
5. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med. 2005;352: 280-91.
6. Savard P, Carroll KC, Wilson LE, Perl TM. The challenges of carbapenemase-producing Enterobacteriaceae and infection prevention: protecting patients in the chaos. Infect Control Hosp Epidemiol. 2013;34: 730-9.
7. Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant Gram-negative bacilli in the United States. Infect Control Hosp Epidemiol. 2010;31(S1): S51-4.
8. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5): 2137-9.
9. Colodner R, Samra Z, Keller N, et al. First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis. 2007;57(2): 201-5.
10. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother. 2009;63: 246-51.
11. Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect. 2009;10: 563-70.
12. Drusano GL, Ambrose P, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55: 2528-31.
13. Clinical and Laboratory Standards Institute (CLSI). Analysis and presentation of cumulative antimicrobial susceptibility test data. 3rd ed. Approved guideline M39-A3. Wayne, PA: CLSI; 2009.
14. Juretschko S, LaBombardi VJ, Lerner SA, Sreckenberger PC. Accuracies of β-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek and Viteck 2). J Clin Microbiol. 2007;45: 1339-42.
15. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol. 2006;70: 140-50.
16. Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;43: 2010-6.
17. Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009;65: 414-26.
18. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29: 996-1011.
19. Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med. 1985;79: 1-7.
20. Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med. 1984;100: 219-22.